Traders should monitor for confirmation of exchange approvals and the final implementation of the share consolidation by April 6, 2026. The move may improve stock liquidity and listing compliance but does not reflect changes in company performance.
Price Chart
Executive Summary
XORTX Therapeutics has delayed the effective date of its planned 1-for-5 share consolidation from March 27, 2026 to April 6, 2026. The change is pending final approvals from the TSX Venture Exchange and Nasdaq.
Key Facts
- Share consolidation (1 new share for every 5 old shares) has been postponed from March 27, 2026 to April 6, 2026.
- The delay is due to pending regulatory approvals from the TSX Venture Exchange and Nasdaq.
- No financial results, clinical updates, or material operational changes were disclosed.
- This is a procedural update related to corporate structure, not a change in business fundamentals.
Financial Impact
No immediate financial impact. The share consolidation, when completed, will reduce the number of outstanding shares by 80% but does not affect market capitalization or enterprise value.
Risk Factors
- Risk that Nasdaq or TSXV may not approve the consolidation, potentially leading to delisting concerns.
- Share consolidation could signal financial distress or low stock price, which may negatively influence investor perception despite no fundamental change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001946 |
| Document: f6k_032626.htm | 0001171843-26-001946 |
| Document: 0001171843-26-001946-index-headers.html | 0001171843-26-001946 |
| Document: 0001171843-26-001946-index.html | 0001171843-26-001946 |
| Document: 0001171843-26-001946.txt | 0001171843-26-001946 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $0.8500 (−39.72%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $0.8500 (−55.73%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $0.8500 (+63.20%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $0.8500 (−63.64%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $0.8500 (−60.65%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $0.8500 (−58.74%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $0.8500 (−61.19%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $0.8500 (+63.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers